



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Evaluation of the Prognostic Value of Ki-67 in Early Stage Breast Cancer

Thesis

*Submitted for Partial Fulfillment of M. Sc. Degree
in Clinical Oncology*

By

Ibrahim Salem Alhussini Ibrahim

Under supervision of

Prof. Dr. Soheir Sayed Ismail

*Professor of Clinical Oncology
Faculty of Medicine, Ain Shams University*

Dr. Amr Lotfy Farag

*Assistant Professor of Clinical Oncology
Faculty of Medicine, Ain Shams University*

Dr. Diaan Eldin Moussa Sherif

*Lecturer of Clinical Oncology
Faculty of Medicine, Ain Shams University*

**Faculty of Medicine
Ain Shams University**

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ رَبِّ اشْرَحْ لِي صَدْرِي ﴿٢٨﴾


وَيَسِّرْ لِي أَمْرِي ﴿٢٩﴾

وَاحْلُلْ عُقْدَةً مِنْ لِسَانِي ﴿٣٠﴾

يَفْقَهُوا قَوْلِي ﴿٣١﴾

صدق الله العظيم

سورة طه الآيات (٢٨-٣١)



Dedication

To my Parents...

Engineer Salem Ibrahim
Albassiouny

Mrs. Azza Ali Albassiouny

My Brother..

Captain Ali Salem Albassiouny

My Sisters..

Mrs. Saly Salem Albassiouny

Mrs. Soha Salem Albassiouny

My wife

Dr. Kholood Mohamed Elshal

And my lovely children

Zain and Lina

Thank you for your unconditional support with my studies. I am honored to have you as my family.

Thank you for giving me a chance to prove and improve myself through all my walks of life.

Thanks for believing in me and for allowing me to further my studies.

I love you.. and will always do.

Acknowledgments

*First of all, thanks to gracious **ALLAH** who guide me to the frank clear way and offers me great assistance of honest professors.*

*I would like to express my deepest gratitude and unlimited thanks to **Prof. Dr. Soheir Sayed Ismail**, Professor and former head of Clinical Oncology & Nuclear Medicine department, Faculty of Medicine, Ain Shams University, for her encouragement, sustained support, expert guidance, valuable instructions and suggestions throughout this work. I feel really honoured to work under her supervision.*

*No word can fulfil the feelings of gratitude and respect I carry to **Dr. Amr Lotfy Farag**, Assistant professor of Clinical Oncology & Nuclear Medicine, Faculty of Medicine, Ain Shams University, who honoured me by his meticulous supervision, fine touches, continuous helps and valuable advices in all the stages of this work.*

*I would like to extend my gratitude and very thanks to **Prof. Dr. Dina Eldin Moussa Sherif**, Lecturer of clinical oncology, Faculty of Medicine, Ain Shams University, for his kind assistance, consumed time and kind supervision all through this work.*

Ibrahim Salem Alhussini Ibrahim

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations.....	iv
Introduction	1
Aim of the Work.....	3
Review of Literature	
Epidemiology of Breast Cancer	4
Risk Factors	7
Screening.....	17
Classification of Breast Cancer	19
Diagnosis of Breast Cancer	29
Staging of Breast Cancer	40
Prognostic and predictive factors.....	45
Ki67 as a Marker of Proliferation.....	72
Patients and Methods.....	88
Results	92
Discussion	125
Summary	132
Conclusion	137
Recommendations	139
References	140
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Common Risk Factors for Breast Cancer.....	13
Table (2):	Definition of Primary T Categories	43
Table (3):	Definition of Clinical Regional Lymph N Categories.....	43
Table (4):	Definition of Pathologic Regional Lymph N Categories	44
Table (5):	Definition of Distant M Categories	44
Table (6):	Patient characteristics	93
Table (7):	Correlation of Ki67 with clinico- pathologic factors.....	100
Table (8):	Correlation of different intrinsic subtypes with clinicopathologic features	105
Table (9):	Disease Free Survival analysis according to Ki67 status	111
Table (10):	Disease Free Survival analysis according to Tumor stage.....	113
Table (11):	Disease Free Survival analysis according to intrinsic subtypes.....	114
Table (12):	Disease Free Survival analysis according to tumor size	117
Table (13):	Disease Free Survival analysis according to Lymph nodes status	119
Table (14):	Disease Free Survival analysis according to Age.....	120
Table (15):	Disease Free Survival analysis according to pathological type	121
Table (16):	Disease Free Survival analysis according ER status	122
Table (17):	Disease Free Survival analysis according PR status	123
Table (18):	Disease Free Survival analysis according Her2 status	124

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Estimated age standardized incidence rates of breast cancer per 100.000 women	4
Figure (2):	Estimated number of new cases in 2018 in Egypt.....	5
Figure (3):	Estimated number of deaths in 2018, worldwide, all cancers.....	6
Figure (4):	Estimated number of deaths in 2018, Egypt, all cancers.....	6
Figure (5):	Genes comprised within the multigene assays.....	53
Figure (6):	Number of patients by age group.....	92
Figure (7):	Histological subtypes in the study group.....	95
Figure (8):	Histological grades in the study group	95
Figure (9):	T & N stage in the study group	96
Figure (10):	Number of patients by stage	96
Figure (11):	Side of disease in the study group	97
Figure (12):	Type of surgery done	97
Figure (13):	Receptors status in the study group.....	98
Figure (14):	Ki 67 status in the study group.....	98
Figure (15):	Clinico-pathological features of study group.....	99
Figure (16):	Events happened by number of patients	99
Figure (17):	Relation between Ki67 status and Tumor stage	103
Figure (18):	Ki67 status in relation to different clinic pathological characteristics.....	104

List of Figures *(Cont...)*

Fig. No.	Title	Page No.
Figure (19):	Disease free survival (DFS) and Ki67.....	112
Figure (20):	Disease free survival (DFS) and Tumor stage	113
Figure (21):	Disease Free survival and intrinsic subtypes	115
Figure (22):	Disease free survival and tumor size	116
Figure (23):	Disease free survival and Lymph nodes status	118
Figure (24):	Disease free survival and Age.....	120
Figure (25):	Disease free survival and pathological type.....	121
Figure (26):	Disease free survival and ER status	122
Figure (27):	Disease free survival and PR status.....	123
Figure (28):	Disease free survival and Her2 status.....	124

List of Abbreviations

Abb.	Full term
ABCSG	<i>Austrian Breast and Colorectal Cancer Study Group</i>
ACS.....	<i>American Cancer Society</i>
ADC	<i>Antibody-Drug Conjugate</i>
AJCC	<i>American Joint Committee on Cancer</i>
Akt	<i>Ak strain transforming</i>
AR.....	<i>Androgen Receptor</i>
ASCO.....	<i>American Society of Clinical Oncology</i>
ASOs.....	<i>Antisense oligodeoxynucleotides</i>
BAG1	<i>Bcl-2-associated athanogene-1</i>
BCI.....	<i>Breast Cancer Index</i>
Bcl-2.....	<i>B-cell lymphoma 2</i>
BIRADS.....	<i>Breast Imaging Reporting and Data System</i>
BL	<i>Basal Like</i>
BMI.....	<i>Body mass index</i>
bp	<i>Base pair</i>
BRCA.....	<i>BReast CAncer gene</i>
CAP.....	<i>College of American Pathologists</i>
CB.....	<i>Core biopsy</i>
CDK	<i>Cyclin-Dependent Kinases</i>
CT	<i>Computerized tomography</i>
DCIS.....	<i>Ductal carcinoma in situ</i>
DFS.....	<i>Disease Free Survival</i>
DNA.....	<i>Deoxyribonucleic acid</i>
EGFR.....	<i>Epidermal Growth Factor Receptor</i>
EPclin score.....	<i>Endo-Predict clinicomolecular score</i>
ER.....	<i>Estrogen receptor</i>
ErbB-2	<i>Erythroblastic oncogene B 2</i>
ERE	<i>Estrogen responsive element</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>ESR1</i>	<i>Estrogen-receptor 1</i>
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>FFPE</i>	<i>Formalin-fixed, paraffin-embedded</i>
<i>FISH</i>	<i>Fluorescence in situ hybridization</i>
<i>FNAC</i>	<i>Fine needle aspiration cytology</i>
<i>FTI</i>	<i>Farnesyl Transferase Inhibitors</i>
<i>GEICAM</i>	<i>Grupo Español de Investigación en Cáncer de Mama</i>
<i>GGI</i>	<i>Genomic Grade Index</i>
<i>gpNMB</i>	<i>Glycoprotein Non-metastatic Melanoma Protein B</i>
<i>GSTM1</i>	<i>Glutathione S-transferase Mu 1</i>
<i>HDAC</i>	<i>Histone Deacetylase</i>
<i>HER2</i>	<i>Human epidermal growth factor receptor 2</i>
<i>HGFR</i>	<i>Hepatocyte growth factor receptor</i>
<i>HR</i>	<i>Hazard Ratio</i>
<i>HR</i>	<i>Hormone receptors</i>
<i>IDCNOS</i>	<i>Invasive ductal carcinoma not otherwise specified</i>
<i>IHC</i>	<i>Immunohistochemistry</i>
<i>IMPAKT</i>	IM Proving cA re and K nowledge through T ranslational research
<i>kDa</i>	<i>kilodalton</i>
<i>KRAS</i>	<i>Kirsten rat sarcoma viral oncogene</i>
<i>LI</i>	<i>labeling index</i>
<i>MAPK</i>	<i>Mitogen-activated protein kinase</i>
<i>MART-1</i>	<i>melanoma antigen recognized by T cells 1</i>
<i>MBC</i>	<i>Metastatic breast cancer</i>
<i>Mib-1</i>	<i>Monoclonal murine antibody 1</i>
<i>MMM</i>	<i>Mucosal malignant melanoma</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>MRI</i>	<i>Magnetic resonance imaging</i>
<i>mTOR</i>	<i>Mammalian target of rapamycin</i>
<i>NCCN</i>	<i>National Comprehensive Cancer Network</i>
<i>NMB</i>	<i>Nonmetastatic Melanoma Protein B</i>
<i>NST</i>	<i>No special type</i>
<i>ORR</i>	<i>Objective response rate</i>
<i>OS</i>	<i>Overall survival</i>
<i>PAM50</i>	<i>Prediction Analysis of Microarray 50</i>
<i>PARP</i>	<i>Poly ADP-ribose Polymerase</i>
<i>PCNA</i>	<i>proliferating cell nuclear antigen</i>
<i>PD-1</i>	<i>Programmed cell death protein 1</i>
<i>PDGFR</i>	<i>Platelet-derived growth factor receptors</i>
<i>PD-L1</i>	<i>Programmed death-ligand 1</i>
<i>PET</i>	<i>Positron emission tomography</i>
<i>PFS</i>	<i>Progression free survival</i>
<i>PI3-K</i>	<i>Phosphatidylinositol 3-Kinase</i>
<i>PICELs</i>	<i>Photo immunoconjugate-encapsulating liposomes</i>
<i>PIK3CA</i>	<i>Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha</i>
<i>PNAs</i>	<i>peptide nucleic acids</i>
<i>PR</i>	<i>Progesterone receptor</i>
<i>PTEN</i>	<i>Phosphatase and tensin homolog</i>
<i>PTEN</i>	<i>Phosphatase and tensin homolog</i>
<i>RAS</i>	<i>Rat sarcoma</i>
<i>REMARK</i>	<i>Reporting Recommendations for Tumour Markers Prognostic Studies</i>
<i>RNAi</i>	<i>Ribonucleic acid interference</i>
<i>ROC</i>	<i>Receiver operator characteristic</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>ROR-P</i>	<i>Risk of recurrence - proliferation genes</i>
<i>ROR-S</i>	<i>Risk of recurrence score</i>
<i>ROR-T</i>	<i>Risk of recurrence - tumour size</i>
<i>RS</i>	<i>Recurrence Score</i>
<i>RTK</i>	<i>Receptor Tyrosine Kinase</i>
<i>RT-PCR</i>	<i>Reverse transcription polymerase chain reaction</i>
<i>SD</i>	<i>Standard Deviation</i>
<i>SERMs</i>	<i>Selective estrogen receptor modulators</i>
<i>shRNAs</i>	<i>short hairpin Ribonucleic acids</i>
<i>SPSS</i>	<i>Statistical Package for the Social Sciences</i>
<i>SRC inhibitor</i>	<i>Sarcoma gene inhibitor</i>
<i>SUV</i>	<i>Standardized uptake value</i>
<i>TAILORx</i>	<i>Trial Assigning Individualized Options for Treatment (Rx)</i>
<i>TILs</i>	<i>Tumour infiltrating lymphocytes</i>
<i>TNBC</i>	<i>Triple negative Breast Cancer</i>
<i>TNM</i>	<i>Tumor-node metastasis</i>
<i>TP53</i>	<i>Tumour protein 53</i>
<i>US</i>	<i>Ultrasonography</i>
<i>USPSTF</i>	<i>United States Preventive Services Task Force</i>
<i>VEGF</i>	<i>Vascular endothelial growth factor</i>
<i>WHO</i>	<i>World Health Organization</i>